KLRS Kalaris Therapeutics, Inc.
Mergers ·
The combined company expects about $100 million in cash at closing to fund operations into the fourth quarter of 2026, while its lead drug candidate, TH103, is still in an open-label Phase 1 trial. Former Kalaris holders own about 74.47% on a fully diluted basis.
Pre-merger Kalaris holders own about 74.47% of the combined company. Cash of about $100 million is expected to last into the fourth quarter of 2026.
At a March 12, 2025 special meeting, AlloVir holders approved the share issuance and change of control under Nasdaq rules, and a stock plan increase. The merger is expected to close as soon as practicable.
AlloVir holders backed all proposals at a special meeting on March 12, 2025. The combined company is expected to be renamed Kalaris Therapeutics and trade on Nasdaq as KLRS.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $30.8 million | $45.0 million |
| Net income (loss) | -$43.4 million | -$69.2 million |
| Cash from operations | -$38.4 million | -$20.7 million |
| Cash and equivalents | $98.1 million | $1.6 million |
| Short-term investments | $19.9 million | $0 |
Our latest story on this, dated Mar 18, 2025: "AlloVir (now Kalaris Therapeutics) completes Kalaris merger; shares to trade as KLRS on March 19". The story links the filing or release it is based on. Read the story.
Kalaris Therapeutics, Inc. trades under the ticker KLRS on NASDAQ.
Kalaris Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Kalaris Therapeutics, Inc. is 1754068. Its filings are on SEC EDGAR.
23,804,981 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Kalaris Therapeutics, Inc. under United States.
Our directory classifies Kalaris Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Kalaris Therapeutics, Inc. is US4829291065.
aibio.space lists Kalaris Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Kalaris Therapeutics, Inc. reported a net loss of $43.4 million for the fiscal year ended Dec 31, 2025, and used $38.4 million of cash in operations, per its annual report to the SEC.
$30.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$93.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Kalaris Therapeutics, dated Mar 18, 2025: "AlloVir (now Kalaris Therapeutics) completes Kalaris merger; shares to trade as KLRS on March 19". The combined company expects about $100 million in cash at closing to fund operations into the fourth quarter of 2026, while its lead drug candidate, TH103, is still in an open-label Phase 1 trial. Former Kalaris holders own about 74.47% on a fully diluted basis. Source.
From our story of Mar 18, 2025: The combined company expects about $100 million in cash at closing to fund operations into the fourth quarter of 2026, while its lead drug candidate, TH103, is still in an open-label Phase 1 trial. Source.
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,2.02,5.01,5.02,5.03,5.06,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 5.02,5.07,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio